1-2 of 2
Keywords: Human epidermal growth factor receptor 2
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Human Epidermal Growth Factor Receptor 2 in Non-Muscle Invasive Bladder Cancer: Issues in Assessment Methods and Its Role as Prognostic/Predictive Marker and Putative Therapeutic Target: A Comprehensive Review

Available to Purchase
Subject Area:
Further Areas
Francesca Sanguedolce, Davide Russo, Vito Mancini, Oscar Selvaggio, Beppe Calò, Giuseppe Carrieri, Luigi Cormio
Journal: Urologia Internationalis
Urol Int (2019) 102 (3): 249–261.
https://doi.org/10.1159/000494359
Published Online: 21 November 2018
...Francesca Sanguedolce; Davide Russo; Vito Mancini; Oscar Selvaggio; Beppe Calò; Giuseppe Carrieri; Luigi Cormio Although human epidermal growth factor receptor 2 (HER2) plays a prognostic and predictive role in breast and gastric cancer, its function in bladder cancer (BC) is still controversial...
View article titled, Human Epidermal Growth Factor Receptor 2 in Non-Muscle Invasive Bladder Cancer: Issues in Assessment Methods and Its Role as Prognostic/Predictive Marker and Putative Therapeutic Target: A Comprehensive Review
Open the PDF for Human Epidermal Growth Factor Receptor 2 in Non-Muscle Invasive Bladder Cancer: Issues in Assessment Methods and Its Role as Prognostic/Predictive Marker and Putative Therapeutic Target: A Comprehensive Review in another window
Journal Articles

Complete and Durable Remission of Human Epidermal Growth Factor Receptor 2-Positive Metastatic Urothelial Carcinoma Following Third-Line Treatment with Trastuzumab and Gemcitabine

Available to Purchase
Subject Area:
Further Areas
Felix Wezel, Philipp Erben, Timo Gaiser, Johannes Budjan, Jost von Hardenberg, Maurice Stephan Michel, Christian Bolenz
Journal: Urologia Internationalis
Urol Int (2018) 100 (1): 122–125.
https://doi.org/10.1159/000443280
Published Online: 19 January 2016
.... Unlike in many other cancers, no clinically established molecular targeted therapies exist for the treatment of this malignancy. Here we present a case of complete tumor remission following third-line treatment with trastuzumab and gemcitabine in a patient with human epidermal growth factor receptor 2...
View article titled, Complete and Durable Remission of Human Epidermal Growth Factor Receptor 2-Positive Metastatic Urothelial Carcinoma Following Third-Line Treatment with Trastuzumab and Gemcitabine
Open the PDF for Complete and Durable Remission of Human Epidermal Growth Factor Receptor 2-Positive Metastatic Urothelial Carcinoma Following Third-Line Treatment with Trastuzumab and Gemcitabine in another window